• Citrato de Sildenafila Biosintetica indications
• Uses of Citrato de Sildenafila Biosintetica in details
• Citrato de Sildenafila Biosintetica description
• Citrato de Sildenafila Biosintetica dosage
• Citrato de Sildenafila Biosintetica interactions
• Citrato de Sildenafila Biosintetica side effects
• Citrato de Sildenafila Biosintetica contraindications

What is Citrato de Sildenafila Biosintetica?

Citrato de Sildenafila Biosintetica is used to treat men who have erectile dysfunction (also called sexual impotence). Citrato de Sildenafila Biosintetica belongs to a group of medicines called phosphodiesterase 5 (PDE5) inhibitors. These medicines prevent an enzyme called phosphodiesterase type-5 from working too quickly. The penis is one of the areas where this enzyme works.

Erectile dysfunction is a condition where the penis does not harden and expand when a man is sexually excited, or when he cannot keep an erection. When a man is sexually stimulated, his body's normal response is to increase blood flow to his penis to produce an erection. By controlling the enzyme, Citrato de Sildenafila Biosintetica helps to maintain an erection after the penis is stroked. Without physical action to the penis, such as that occurring during sexual intercourse, Citrato de Sildenafila Biosintetica will not work to cause an erection.

Citrato de Sildenafila Biosintetica is also used in both men and women to treat the symptoms of pulmonary arterial hypertension. This is a type of high blood pressure that occurs between the heart and the lungs. When hypertension occurs in the lungs, the heart must work harder to pump enough blood through the lungs. Citrato de Sildenafila Biosintetica works on the PDE5 enzyme in the lungs to relax the blood vessels. This will increase the supply of blood to the lungs and reduce the workload of the heart.

Citrato de Sildenafila Biosintetica is available only with your doctor's prescription.

Citrato de Sildenafila Biosintetica indications

Citrato de Sildenafila Biosintetica is indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in adults to improve exercise ability and delay clinical worsening. The delay in clinical worsening was demonstrated when Citrato de Sildenafila Biosintetica was added to background epoprostenol therapy.

Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II–III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%).

Limitation of Use: Adding Citrato de Sildenafila Biosintetica to bosentan therapy does not result in any beneficial effect on exercise capacity.

How should I use Citrato de Sildenafila Biosintetica?

Use Citrato de Sildenafila Biosintetica suspension as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• An extra patient leaflet with detailed instructions for use is available with Citrato de Sildenafila Biosintetica suspension. Talk to your pharmacist if you have questions about this information.
• Take Citrato de Sildenafila Biosintetica suspension by mouth with or without food. Take your doses 4 to 6 hours apart unless your doctor tells you otherwise.
• Shake well for at least 10 seconds before each use.
• Use the oral dosing syringe that comes with Citrato de Sildenafila Biosintetica suspension to measure your dose. Ask your pharmacist for help if you are unsure of how to measure your dose.
• Do not mix Citrato de Sildenafila Biosintetica suspension with other medicine or flavoring.
• Wash and dry the dosing syringe after each use.
• Take Citrato de Sildenafila Biosintetica suspension on a regular schedule to get the most benefit from it. Take it at the same times each day.
• Continue to take Citrato de Sildenafila Biosintetica suspension even if you feel well. Do not miss any doses.
• Do not suddenly stop taking Citrato de Sildenafila Biosintetica suspension or change your dose without talking to your doctor.
• If you miss a dose of Citrato de Sildenafila Biosintetica suspension, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Citrato de Sildenafila Biosintetica suspension.

Uses of Citrato de Sildenafila Biosintetica in details

Use: Labeled Indications

Erectile dysfunction: Citrato de Sildenafila Biosintetica: Treatment of erectile dysfunction.

Pulmonary arterial hypertension: Citrato de Sildenafila Biosintetica: Treatment of pulmonary arterial hypertension (WHO group I; efficacy established predominately in patients with WHO/NYHA functional class II and III) in adults to improve exercise ability and delay clinical worsening.

Off Label Uses

High-altitude pulmonary edema

Based on the 2019 Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness, Citrato de Sildenafila Biosintetica is a recommended option for the prevention and treatment of high-altitude pulmonary edema (as an adjunct to descent, oxygen, or portable hyperbaric therapy). Supplemental oxygen and descent are the mainstays of treatment. For prevention, Citrato de Sildenafila Biosintetica should only be considered for patients with a history of high-altitude pulmonary edema, especially multiple episodes.

Raynaud phenomenon

Data from a meta-analysis and small controlled trials support the use of Citrato de Sildenafila Biosintetica for Raynaud phenomenon related to systemic sclerosis, demonstrating a decrease in the frequency and severity of attacks.

Citrato de Sildenafila Biosintetica description

Each film-coated tablet contains Sildenafil citrate equivalent to 50 mg Citrato de Sildenafila Biosintetica.

Each film-coated tablet contains Sildenafil citrate equivalent to 100 mg Citrato de Sildenafila Biosintetica.

Each orodispersible tablet contains Sildenafil citrate equivalent to 50 mg Citrato de Sildenafila Biosintetica.

Excipients/Inactive Ingredients: Film-Coated Tablets: In addition to the active ingredient, Citrato de Sildenafila Biosintetica citrate, each tablet contains the following inactive ingredients: Microcrystalline cellulose, calcium hydrogen phosphate (anhydrous), croscarmellose sodium, magnesium stearate, hydroxypropyl methylcellulose (hypromellose), titanium dioxide (E171), lactose, triacetin, and FD & C Blue #2 aluminum lake [indigo carmine aluminum lake (E132)].

Orodispersible Tablets: In addition to the active ingredient, Citrato de Sildenafila Biosintetica citrate, each orodispersible tablet contains the following inactive ingredients: Microcrystalline cellulose, silica hydrophobic colloidal, croscarmellose sodium, magnesium stearate, indigo carmine aluminium lake (E132), sucralose, mannitol, crospovidone, polyvinyl acetate, povidone, flavouring (contains: Maltodextrin and dextrin), natural flavouring (contains: Maltodextrin, E422 glycerol and E1520 propylene glycol), lemon flavouring (contains: Maltodextrin and E307 alpha tocopherol).

Citrato de Sildenafila Biosintetica dosage

Citrato de Sildenafila Biosintetica Dosage

Generic name: Citrato de Sildenafila Biosintetica CITRATE 20mg

Dosage form: tablet, film coated; injection; oral powder

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Citrato de Sildenafila Biosintetica Tablets and

Oral Suspension

The recommended dose of Citrato de Sildenafila Biosintetica is 5 mg or 20 mg three times a day. Administer Citrato de Sildenafila Biosintetica doses 4–6 hours apart.

In the clinical trial no greater efficacy was achieved with the use of higher doses. Treatment with doses higher than 20 mg three times a day is not recommended.

Citrato de Sildenafila Biosintetica Injection

Citrato de Sildenafila Biosintetica injection is for the continued treatment of patients with PAH who are currently prescribed oral Citrato de Sildenafila Biosintetica and who are temporarily unable to take oral medication.

The recommended dose is 2.5 mg or 10 mg administered as an intravenous bolus injection three times a day. The dose of Citrato de Sildenafila Biosintetica injection does not need to be adjusted for body weight.

A 10 mg dose of Citrato de Sildenafila Biosintetica injection is predicted to provide pharmacological effect of Citrato de Sildenafila Biosintetica and its N-desmethyl metabolite equivalent to that of a 20 mg oral dose.

Reconstitution of the Powder for

Oral Suspension

1. Tap the bottle to release the powder.
2. Remove the cap.
3. Accurately measure out 60 mL of water and pour the water into the bottle. (Figure 1)

   Figure 1

4. Replace the cap and shake the bottle vigorously for a minimum of 30 seconds. (Figure 2)

   Figure 2

5. Remove the cap.
6. Accurately measure out another 30 mL of water and add this to the bottle. You should always add a total of 90 mL of water irrespective of the dose prescribed. (Figure 3)

   Figure 3

7. Replace the cap and shake the bottle vigorously for a minimum of 30 seconds. (Figure 4)

   Figure 4

8. Remove the cap.
9. Press the bottle adaptor into the neck of the bottle (as shown on Figure 5, below). The adaptor is provided so that you can fill the oral syringe with medicine from the bottle. Replace the cap on the bottle.

   Figure 5

10. Write the expiration date of the constituted oral suspension on the bottle label (the expiration date of the constituted oral suspension is 60 days from the date of constitution).

Incompatibilities

Do not mix with any other medication or additional flavoring agent.

More about Citrato de Sildenafila Biosintetica (Citrato de Sildenafila Biosintetica)

• Side Effects
• During Pregnancy
• Dosage Information
• Drug Images
• Drug Interactions
• Support Group
• Pricing & Coupons
• 6 Reviews - Add your own review/rating
• Generic Availability

Consumer resources

• Citrato de Sildenafila Biosintetica
• Citrato de Sildenafila Biosintetica Injection
• Citrato de Sildenafila Biosintetica suspension
• Citrato de Sildenafila Biosintetica (Advanced Reading)
• Citrato de Sildenafila Biosintetica

  Intravenous (Advanced Reading)

• Other brands: Citrato de Sildenafila Biosintetica

Professional resources

• Citrato de Sildenafila Biosintetica (FDA)
• Citrato de Sildenafila Biosintetica Citrate (AHFS Monograph)

Related treatment guides

• Pulmonary Hypertension

Citrato de Sildenafila Biosintetica interactions

See also:
What other drugs will affect Citrato de Sildenafila Biosintetica?

Effects of Other Drugs on Citrato de Sildenafila Biosintetica Citrato de Sildenafila Biosintetica Citrate

In Vitro Studies: Citrato de Sildenafila Biosintetica Citrato de Sildenafila Biosintetica metabolism is principally mediated by the cytochrome P450 (CYP) isoforms 3A4 (major route) and 2C9 (minor route). Therefore, inhibitors of these isoenzymes may reduce Citrato de Sildenafila Biosintetica clearance.

In Vivo Studies: Cimetidine (800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma Citrato de Sildenafila Biosintetica concentrations when coadministered with Citrato de Sildenafila Biosintetica citrate (50 mg) to healthy volunteers.

When a single 100 mg dose of Citrato de Sildenafila Biosintetica citrate was administered with erythromycin, a specific CYP3A4 inhibitor, at steady state (500 mg bid for 5 days), there was a 182% increase in Citrato de Sildenafila Biosintetica systemic exposure (AUC). In addition, coadministration of the HIV protease inhibitor saquinavir, also a CYP3A4 inhibitor, at steady state (1200 mg tid) with Citrato de Sildenafila Biosintetica citrate (100 mg single dose) resulted in a 140% increase in Citrato de Sildenafila Biosintetica C_max and a 210% increase in Citrato de Sildenafila Biosintetica AUC. Citrato de Sildenafila Biosintetica Citrato de Sildenafila Biosintetica citrate had no effect on saquinavir pharmacokinetics. Stronger CYP3A4 inhibitors such as ketoconazole or itraconazole would be expected to have still greater effects, and population data from patients in clinical trials did indicate a reduction in Citrato de Sildenafila Biosintetica clearance when it was coadministered with CYP3A4 inhibitors (such as ketoconazole, erythromycin, or cimetidine).

Coadministration with the HIV protease inhibitor ritonavir, which is a highly potent P450 inhibitor, at steady state (400 mg bid) with Citrato de Sildenafila Biosintetica citrate (100 mg single dose) resulted in a 300% (4-fold) increase in Citrato de Sildenafila Biosintetica C_max and a 1000% (11-fold) increase in Citrato de Sildenafila Biosintetica plasma AUC. At 24 hours the plasma levels of Citrato de Sildenafila Biosintetica were still approximately 200 ng/mL, compared to approximately 5 ng/mL when Citrato de Sildenafila Biosintetica was dosed alone. This is consistent with ritonavirs marked effects on a broad range of P450 substrates. Citrato de Sildenafila Biosintetica Citrato de Sildenafila Biosintetica citrate had no effect on ritonavir pharmacokinetics.

It can be expected that concomitant administration of CYP3A4 inducers, such as rifampin, will decrease plasma levels of Citrato de Sildenafila Biosintetica.

Single doses of antacid (magnesium hydroxide/aluminum hydroxide) did not affect the bioavailability of Citrato de Sildenafila Biosintetica citrate.

Pharmacokinetic data from patients in clinical trials showed no effect on Citrato de Sildenafila Biosintetica pharmacokinetics of CYP2C9 inhibitors (such as tolbutamide, warfarin), CYP2D6 inhibitors (such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related diuretics, ACE inhibitors, and calcium channel blockers. The AUC of the active metabolite, N-desmethyl Citrato de Sildenafila Biosintetica, was increased 62% by loop and potassium-sparing diuretics and 102% by nonspecific beta-blockers. These effects on the metabolite are not expected to be of clinical consequence.

Effects of Citrato de Sildenafila Biosintetica Citrato de Sildenafila Biosintetica Citrate on Other Drugs

In Vitro Studies: Citrato de Sildenafila Biosintetica Citrato de Sildenafila Biosintetica is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 (IC50 >150 mM). Given Citrato de Sildenafila Biosintetica peak plasma concentrations of approximately 1 mcM after recommended doses, it is unlikely that Citrato de Sildenafila Biosintetica citrate will alter the clearance of substrates of these isoenzymes.

In Vivo Studies: When Citrato de Sildenafila Biosintetica citrate 100 mg oral was coadministered with amlodipine, 5 mg or 10 mg oral, to hypertensive patients, the mean additional reduction on supine blood pressure was 8 mmHg systolic and 7 mmHg diastolic.

No significant interactions were shown with tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolized by CYP2C9.

Citrato de Sildenafila Biosintetica Citrato de Sildenafila Biosintetica citrate (50 mg) did not potentiate the increase in bleeding time caused by aspirin (150 mg).

Citrato de Sildenafila Biosintetica Citrato de Sildenafila Biosintetica citrate (50 mg) did not potentiate the hypotensive effect of alcohol in healthy volunteers with mean maximum blood alcohol levels of 0.08%.

Citrato de Sildenafila Biosintetica Citrato de Sildenafila Biosintetica (100 mg) did not affect the steady state pharmacokinetics of the HIV protease inhibitors, saquinavir and ritonavir, both of which are CYP3A4 substrates.

Citrato de Sildenafila Biosintetica side effects

See also:
What are the possible side effects of Citrato de Sildenafila Biosintetica?

The following serious adverse events are discussed elsewhere in the labeling:

• Mortality with pediatric use
• Hypotension
• Vision loss
• Hearing loss
• Priapism
• Vaso-occlusive crisis

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Safety data of Citrato de Sildenafila Biosintetica in adults were obtained from the 12-week, placebo-controlled clinical study (Study 1) and an open-label extension study in 277 Citrato de Sildenafila Biosintetica-treated patients with PAH, WHO Group I.

The overall frequency of discontinuation in Citrato de Sildenafila Biosintetica-treated patients on 20 mg three times a day was 3% and was the same for the placebo group.

In Study 1, the adverse reactions that were reported by at least 3% of Citrato de Sildenafila Biosintetica-treated patients (20 mg three times a day) and were more frequent in Citrato de Sildenafila Biosintetica-treated patients than in placebo-treated patients are shown in Table 1. Adverse reactions were generally transient and mild to moderate in nature.

Table 1: Most Common Adverse Reactions in Patients with PAH in Study 1 (More Frequent in Citrato de Sildenafila Biosintetica-Treated Patients than Placebo-Treated Patients and Incidence ≥ 3% in Citrato de Sildenafila Biosintetica-Treated Patients)

	Placebo, % (n = 70)	Citrato de Sildenafila Biosintetica 20 mg three times a day, % (n = 69)	Placebo-Subtracted, %
Epistaxis	1	9	8
Headache	39	46	7
Dyspepsia	7	13	6
Flushing	4	10	6
Insomnia	1	7	6
Erythema	1	6	5
Dyspnea exacerbated	3	7	4
Rhinitis	0	4	4
Diarrhea	6	9	3
Myalgia	4	7	3
Pyrexia	3	6	3
Gastritis	0	3	3
Sinusitis	0	3	3
Paresthesia	0	3	3

At doses higher than the recommended 20 mg three times a day, there was a greater incidence of some adverse reactions including flushing, diarrhea, myalgia and visual disturbances. Visual disturbances were identified as mild and transient, and were predominately color-tinge to vision, but also increased sensitivity to light or blurred vision.

The incidence of retinal hemorrhage with Citrato de Sildenafila Biosintetica 20 mg three times a day was 1.4% versus 0% placebo and for all Citrato de Sildenafila Biosintetica doses studied was 1.9% versus 0% placebo. The incidence of eye hemorrhage at both 20 mg three times a day and at all doses studied was 1.4% for Citrato de Sildenafila Biosintetica versus 1.4% for placebo. The patients experiencing these reactions had risk factors for hemorrhage including concurrent anticoagulant therapy.

In a placebo-controlled fixed dose titration study (Study 2) of Citrato de Sildenafila Biosintetica (starting with recommended dose of 20 mg and increased to 40 mg and then 80 mg all three times a day) as an adjunct to intravenous epoprostenol in patients with PAH, the adverse reactions that were more frequent in the Citrato de Sildenafila Biosintetica + epoprostenol group than in the epoprostenol group (greater than 6% difference) are shown in Table 2.

Table 2: Adverse Reactions (%) in patients with PAH in Study 2 (incidence in Citrato de Sildenafila Biosintetica + Epoprostenol group at least 6% greater than Epoprostenol group)

	Citrato de Sildenafila Biosintetica + Epoprostenol (n = 134)	Epoprostenol (n = 131)	(Citrato de Sildenafila Biosintetica + Epoprostenol) minus Epoprostenol
Headache	57	34	23
Edema^	25	13	14
Dyspepsia	16	2	14
Pain in extremity	17	6	11
Diarrhea	25	18	7
Nausea	25	18	7
Nasal congestion	9	2	7
^includes peripheral edema

Citrato de Sildenafila Biosintetica Injection

Citrato de Sildenafila Biosintetica injection was studied in a 66-patient, placebo-controlled study in patients with PAH at doses targeting plasma concentrations between 10 and 500 ng/mL (up to 8 times the exposure of the recommended dose). Adverse events with Citrato de Sildenafila Biosintetica injection were similar to those seen with oral tablets.

Postmarketing Experience

The following adverse reactions have been identified during post approval use of Citrato de Sildenafila Biosintetica (marketed for both PAH and erectile dysfunction). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Cardiovascular Events

In postmarketing experience with Citrato de Sildenafila Biosintetica at doses indicated for erectile dysfunction, serious cardiovascular, cerebrovascular, and vascular events, including myocardial infarction, sudden cardiac death, ventricular arrhythmia, cerebrovascular hemorrhage, transient ischemic attack, hypertension, pulmonary hemorrhage, and subarachnoid and intracerebral hemorrhages have been reported in temporal association with the use of the drug. Most, but not all, of these patients had preexisting cardiovascular risk factors. Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of Citrato de Sildenafila Biosintetica without sexual activity. Others were reported to have occurred hours to days after use concurrent with sexual activity. It is not possible to determine whether these events are related directly to Citrato de Sildenafila Biosintetica, to sexual activity, to the patient's underlying cardiovascular disease, or to a combination of these or other factors.

Nervous system

Seizure, seizure recurrence

Citrato de Sildenafila Biosintetica contraindications

See also:
What is the most important information I should know about Citrato de Sildenafila Biosintetica?

Do not take Citrato de Sildenafila Biosintetica if you are also using a nitrate drug for chest pain or heart problems. This includes nitroglycerin (Nitrostat, Nitrolingual, Nitro-Dur, Nitro-Bid, and others), isosorbide dinitrate (Dilatrate-SR, Isordil, Sorbitrate), and isosorbide mononitrate (Imdur, ISMO, Monoket). Nitrates are also found in some recreational drugs such as amyl nitrate or nitrite ("poppers"). Taking Citrato de Sildenafila Biosintetica with a nitrate medicine can cause a sudden and serious decrease in blood pressure.

During sexual activity, if you become dizzy or nauseated, or have pain, numbness, or tingling in your chest, arms, neck, or jaw, stop and call your doctor right away. You could be having a serious side effect of Citrato de Sildenafila Biosintetica.

Do not take Citrato de Sildenafila Biosintetica more than once a day. Allow 24 hours to pass between doses. Do not take Citrato de Sildenafila Biosintetica while also taking Citrato de Sildenafila Biosintetica, unless your doctor tells you to.

Contact your doctor or seek emergency medical attention if your erection is painful or lasts longer than 4 hours. A prolonged erection (priapism) can damage the penis.

Citrato de Sildenafila Biosintetica can decrease blood flow to the optic nerve of the eye, causing sudden vision loss. This has occurred in a small number of people taking Citrato de Sildenafila Biosintetica, most of whom also had heart disease, diabetes, high blood pressure, high cholesterol, or certain pre-existing eye problems, and in those who smoke or are over 50 years old. It is not clear whether Citrato de Sildenafila Biosintetica is the actual cause of vision loss.

Stop using Citrato de Sildenafila Biosintetica and get emergency medical help if you have sudden vision loss.

Active ingredient matches for Citrato de Sildenafila Biosintetica:

Sildenafil in Brazil.

List of Citrato de Sildenafila Biosintetica substitutes (brand and generic names)	Sort by popularity
Unit description / dosage (Manufacturer)	Price, USD
Citrato de Sildenafila Teuto (Brazil)
Cobra 100
Cobra 25
Cobra 50
Confidence
Confidence 50mg TAB / 4 (Skama Biotech)	$ 1.11
Confidence 50 mg Tablet (Skama Biotech)	$ 0.28
Cupid (Ethiopia, Sri Lanka)
Cupid 50 mg x 10 Blister x 1 Tablet
Cupid 50 (Philippines)
Cupid 50 50 mg x 10's
D Lira (Peru)
Darculin (Philippines)
Davigor (Ecuador)
Daygra (Vietnam)
Daygra 50 mg x 1 Blister x 4 Tablet
Daygra 100 mg x 1 Blister x 4 Tablet
Daygra 50 mg x 10 Packs x 1 g
Defil (Ecuador)
Degra (Georgia, Turkey)
Dejavú (Brazil)
Denargra (South Korea)
Desilmax (Peru)
Desilmax 50 mg x 1 Blister x 4 Tablet
Desilmax 100 mg x 1 Blister x 4 Tablet
Dialex (Greece)
Dialex Aminophylline 100 mg, Ammoniumchloride 100 mg, Sodiumcitrate 50 mg. SYR / 100ml (Dr Reddy Laboratories Ltd)	$ 0.17
100ml (Dr Reddy Laboratories Ltd)	$ 0.17
Dialex 100 ml Syrup (Dr Reddy Laboratories Ltd)	$ 0.01
DIALEX syr 100ml (Dr Reddy Laboratories Ltd)	$ 0.17
DILKHUSH
DILKHUSH 100MG TABLET 1 strip / 4 tablets each (Torque Pharmaceuticals Pvt Ltd)	$ 0.14
Dinagram (Paraguay)
Dinamico (Bosnia & Herzegowina, Croatia (Hrvatska))
Direktan 100 mg (Austria)
Direktan 25 mg (Austria)
Direktan 50 mg (Austria)
Dirtop (Chile)
Tablet, Film-Coated; Oral; Sildenafil 100 mg (Medipharm)
Tablet, Film-Coated; Oral; Sildenafil 50 mg (Medipharm)
Tablets, Film-Coated; Oral; Sildenafil 100 mg (Medipharm)
Tablets, Film-Coated; Oral; Sildenafil 50 mg (Medipharm)
Diserec (Colombia)
Disilden (Chile)
Tablet, Film-Coated; Oral; Sildenafil Citrate 100 mg
Tablet, Film-Coated; Oral; Sildenafil Citrate 50 mg
Tablets, Film-Coated; Oral; Sildenafil Citrate 100 mg
Tablets, Film-Coated; Oral; Sildenafil Citrate 50 mg
DOUBLE FORCE
DOUBLE FORCE TABLET 1 strip / 5 tablets each (Shrinivas Gujarat Laboratories Pvt Ltd)	$ 0.36
Double Force 100mg Tablet (Shrinivas Gujarat Laboratories Pvt Ltd)	$ 0.07
Dragul (Spain)
See 1998 substitutes for Citrato de Sildenafila Biosintetica

References

1. PubChem. "sildenafil". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
2. DrugBank. "sildenafil". http://www.drugbank.ca/drugs/DB00203 (accessed September 17, 2018).
3. MeSH. "Urological Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Citrato de Sildenafila Biosintetica are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Citrato de Sildenafila Biosintetica. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 22 here

Information checked by Dr. Sachin Kumar, MD Pharmacology